Changes in the proportions of CD4(+)T cell subsets defined by CD127 and CD25 expression during HBV infection

Hong-Tao Xu; Jun Ye; Ya-Bao Chen; Li-Xing Zhang; Jun-Xing Huang; Jian-Chun Xian; Ling Liu; Hai-Lin Peng; Lin Li; Mei Lin; Jing-Hua Huang

doi:10.3109/08820139.2011.631656

Changes in the proportions of CD4(+)T cell subsets defined by CD127 and CD25 expression during HBV infection

Immunol Invest. 2012;41(3):290-303. doi: 10.3109/08820139.2011.631656. Epub 2011 Nov 28.

Authors

Hong-Tao Xu¹, Jun Ye, Ya-Bao Chen, Li-Xing Zhang, Jun-Xing Huang, Jian-Chun Xian, Ling Liu, Hai-Lin Peng, Lin Li, Mei Lin, Jing-Hua Huang

Affiliation

¹ Department of Laboratory Medicine, The Taizhou People's Hospital, Taizhou City, Jiangsu Province 225300, China.

PMID: 22122423
DOI: 10.3109/08820139.2011.631656

Abstract

CD4(+)T cell counts are closely related to the progression of HBV infection. Here, we investigated how the proportions of three CD4(+)T cell subsets - CD127(-)CD25(-), CD127(+)CD25(low/-) and CD127(low)CD25(high) - changed during HBV infection, as is little known. Compared with healthy controls, the proportions of CD127(-)CD25(-) in chronic hepatitis B (CHB) patients and HBV carriers significantly increased, while that of CD127(+)CD25(low/-) significantly decreased. The proportion of CD127(low)CD25(high) in CHB patients was significantly higher than those in HBV carriers or healthy controls. Compared with HBV-DNA negative group, the proportion of CD127(-)CD25(-) in positive group significantly decreased and that of CD127(+)CD25(low/-) significantly increased. In the follow-up study for CHB patients treated with interferon-α2b for 12 weeks or 24 weeks, the proportions of CD127(-)CD25(-) significantly decreased, while that of CD127(low/-)CD25(high) significantly increased. The results suggested that specific changes in the fraction of CD4(+)T cell subsets expressing CD127 and/or CD25 were associated with hepatitis B progression.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / immunology
CD4-Positive T-Lymphocytes / metabolism*
CD4-Positive T-Lymphocytes / pathology
CD4-Positive T-Lymphocytes / virology
Cell Differentiation / drug effects
Cell Proliferation / drug effects
China
Disease Progression
Female
Follow-Up Studies
Hepatitis B virus / immunology*
Hepatitis B virus / pathogenicity
Hepatitis B, Chronic / drug therapy
Hepatitis B, Chronic / immunology*
Hepatitis B, Chronic / physiopathology
Humans
Immunophenotyping
Immunotherapy*
Interferon-alpha / administration & dosage
Interferon-alpha / adverse effects
Interleukin-2 Receptor alpha Subunit / metabolism
Interleukin-7 Receptor alpha Subunit / metabolism
Male
Middle Aged
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism*
T-Lymphocyte Subsets / pathology
T-Lymphocyte Subsets / virology
Young Adult

Substances

Antiviral Agents
Interferon-alpha
Interleukin-2 Receptor alpha Subunit
Interleukin-7 Receptor alpha Subunit
interferon-alpha 8